TaiMed Biologics to present late-breaking Phase IIa data at CROI 2025 on long-acting TMB-365/TMB-380 regimen for HIV maintenance therapy
TMB-365/TMB-380 is a promising long-acting combination of broadly neutralizing antibodies (bNAbs) with complementary mechanisms of action, offering a complete switch regimen for HIV treatment without the need for susceptibility screening. A single infusion every 8 weeks is safe and can maintain HIV suppression with potential for wider application.
Read the full company press release here.
TaiMed marketing partner, Theratechnologies Inc announcement of presentation from Virologic Suppression Data from the PROMISE-US Trial of ibalizumab at CROI
TaiMed marketing partner, Theratechnologies Inc., presented data from a real-world, observational, registry study demonstrating the efficacy and safety of ibalizumab in reducing HIV RNA to undetectable levels in heavily treatment-experienced patients with multidrug-resistant HIV.
Read the full company press release here.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.